



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,624	02/14/2002	Wenyuan Shi	061818-5512 US	2797
34055	7590	10/31/2007	EXAMINER	
PERKINS COIE LLP			ZEMAN, ROBERT A	
POST OFFICE BOX 1208			ART UNIT	
SEATTLE, WA 98111-1208			PAPER NUMBER	
			1645	
			MAIL DATE	
			DELIVERY MODE	
			10/31/2007	
			PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



# UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, DC 20231  
www.uspto.gov

APPLICATION NO./ CONTROL NO. <b>10/077,624</b>	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION Shi, Wenyuan	ATTORNEY DOCKET NO.
--	-------------	---	---------------------

EXAMINER

Robert A. Zeman

ART UNIT

PAPER

1645

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

Commissioner of Patents

The communication filed on **4-23-2007** is not fully responsive to the Office communication mailed **9-13-2006** for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

Since the above mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of ONE (1) MONTH or THIRTY DAYS from the mailing date of this notice, which ever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER C.F.R. 1.136(a).

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio  
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. Mailed to:  
Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 22313-1450  
Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:  
U.S. Patent and Trademark Office  
Mail Stop Sequence  
Customer Window

Randolph Building  
401 Dulaney Street  
Alexandria, VA 22314

Any inquiry concerning this communication should be directed to Examiner Robert A. Zeman, Art Unit 1645, whose telephone number is (571) 272-0866.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

A handwritten signature in black ink, appearing to read "Robert A. Zeman", written in a cursive style.

ROBERT A. ZEMAN  
PRIMARY EXAMINER

<b>Notice to Comply</b>	Application No. 10/077,624	Applicant(s) Shi et al.	
	Examiner Robert A. Zeman	Art Unit 1645	

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951  
For CRF Submission Help, call (571) 272-2510  
PatentIn Software Program Support  
Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845  
PatentIn Software is Available At [www.USPTO.gov](http://www.USPTO.gov)

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

=====

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Wed Jun 06 13:00:52 EDT 2007

=====

\*\*\*\*\*

Reviewer Comments:

Seq Id 15,16,17 has an invalid response for <213>. If <213> responses  
are Artificial or Unknown please give the source of genetic material.  
The response mentioned is not sufficient.

\*\*\*\*\*

Application No:

10077624

Version No:

2.0

Input Set:

Output Set:

Started: 2007-06-05 17:45:55.806

Finished: 2007-06-05 17:45:57.165

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 359 ms

Total Warnings: 31

Total Errors: 0

No. of SeqIDs Defined: 31

Actual SeqID Count: 31

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)

Input Set:

Output Set:

Started: 2007-06-05 17:45:55.806  
Finished: 2007-06-05 17:45:57.165  
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 359 ms  
Total Warnings: 31  
Total Errors: 0  
No. of SeqIDs Defined: 31  
Actual SeqID Count: 31

Error code

Error Description

This error has occurred more than 20 times, will not be displayed

# SEQUENCE LISTING

<110> THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Shi, Wenyan

Morrison, Sherie

Trinh, Kham

Wims, Letitia

Chen, Li

Anderson, Maxwell

Qi, Fengxia

<120> ANTI-MICROBIAL TARGETING CHIMERIC PHARMACEUTICAL

<130> 59157.8007.US01

<140> 10077624

<141> 2002-02-14

<150> US 09/910,358

<151> 2001-07-19

<150> US 09/378,577

<151> 1999-08-20

<160> 31

<170> PatentIn version 3.1

<210> 1

<211> 563

<212> DNA

<213> Artificial sequence

<220>

<223> Synthesized using sequential PCR techniques

<400> 1

ggatatccac catggacttc gggttgagct tggttttect tgtccttact ttaaaaggtg 60

tccagtgtga tagccacgct aagcggcacc acggatataa gcggaagttc cacgagaagc 120

accactcgca cagaggatac tctggtggcg gtggctcggg cggaggtggg tcgggtggcg 180

gcggatccga cgtgaagctt gtggagtctg ggggaggctt agtgaaccct ggagggtccc 240

tgaaactctc ctgtgcagcc tctggattca ctttcagtag ctataccatg tcttgggttc 300

gccagactcc ggagaagagg ctggagtggg tcgcatccat tagtagtggt ggtacttaca 360

cctactatcc agacagtgtg aagggccgat tcaccatctc cagagacaat gccaagaaca 420

ccctgtacct gcaaatgacc agtctgaagt ctgaggacac agccatgtat tactgttcaa 480

gagatgacgg ctcctacggc tcctattact atgctatgga ctactggggt caaggaacct 540

cagtcaccgt ctcttcagct agc 563



<210> 2  
<211> 24  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 2

Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys Phe His Glu  
1 5 10 15

Lys His His Ser His Arg Gly Tyr  
20

<210> 3  
<211> 16  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 3

Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
1 5 10 15

<210> 4  
<211> 165  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 4

Asp Ser His Ala Lys Arg His His Gly Tyr Lys Arg Lys Phe His Glu  
1 5 10 15

Lys His His Ser His Arg Gly Tyr Ser Gly Gly Gly Gly Ser Gly Gly  
20 25 30

Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Lys Leu Val Glu Ser Gly  
35 40 45

Gly Gly Leu Val Asn Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala  
50 55 60

Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr  
65 70 75 80

Pro Glu Lys Arg Leu Glu Trp Val Ala Ser Ile Ser Ser Gly Gly Thr  
85 90 95

Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg  
100 105 110

Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Thr Ser Leu Lys Ser  
115 120 125

Glu Asp Thr Ala Met Tyr Tyr Cys Ser Arg Asp Asp Gly Ser Tyr Gly  
130 135 140

Ser Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr  
145 150 155 160

Val Ser Ser Ala Ser  
165

<210> 5  
<211> 533  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 5  
ggatatccac catggacttc gggttgagct tggttttcct tgtccttact ttaaaagggtg 60  
tccagtgtaa gcggctgttt aaggagctca agttcagcct gcgcaagtac tctgggtggcg 120  
gtggctcggg cggagggtggg tcgggtggcg gcggatccga cgtgaagctt gtggagtctg 180  
ggggaggctt agtgaaccct ggagggtccc tgaaactctc ctgtgcagcc tctggattca 240  
ctttcagtag ctataccatg tcttgggttc gccagactcc ggagaagagg ctggagtggg 300  
tcgcatccat tagtagtggt ggtacttaca cctactatcc agacagtgtg aagggccgat 360  
tcaccatctc cagagacaat gccagaaca cctgtacct gcaaatgacc agtctgaagt 420  
ctgaggacac agccatgtat tactgttcaa gagatgacgg ctctacggc tcctattact 480  
atgctatgga ctactggggt caaggaacct cagtcaccgt ctcttcagct agc 533

<210> 6  
<211> 14  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 6

Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr  
1 5 10

<210> 7  
<211> 155  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Synthesized using sequential PCR techniques

<400> 7

Lys Arg Leu Phe Lys Glu Leu Lys Phe Ser Leu Arg Lys Tyr Ser Gly  
1 5 10 15

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val  
20 25 30

Lys Leu Val Glu Ser Gly Gly Gly Leu Val Asn Pro Gly Gly Ser Leu  
35 40 45

Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met  
50 55 60

Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala Ser  
65 70 75 80

Ile Ser Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys Gly  
85 90 95

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln  
100 105 110

Met Thr Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ser Arg  
115 120 125

Asp Asp Gly Ser Tyr Gly Ser Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly

Gln Gly Thr Ser Val Thr Val Ser Ser Ala Ser  
145                      150                      155

<210> 8  
<211> 89  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 986

<400> 8  
caccactcgc acagaggata ctctggtggc ggtggctcgg gcggagggtgg gtcgggtggc 60  
  
ggcggatccg acgtgaagct tgtggagtc 89

<210> 9  
<211> 84  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 987

<400> 9  
ggtgtccagt gtgatagcca cgctaagcgg caccacggat ataagcggaa gttccacgag 60  
  
aagcaccact cgcacagagg atac 84

<210> 10  
<211> 74  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 988

<400> 10  
gatatccacc atggacttcg gggtgagctt gggtttcctt gtccttactt taaaagggtgt 60  
  
ccagtgtgat agcc 74

<210> 11  
<211> 87  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 989

<400> 11.  
gttcagcctg cgcaagtact ctggtggcgg tggctcgggc ggaggtgggt cgggtggcgg 60  
  
cggatccgac gtgaagcttg tggagtc 87

<210> 12  
<211> 69  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 990

<400> 12  
gtccttactt taaaagggtg ccagtgtgtaag cggctgttta aggagctcaa gttcagcctg 60  
  
cgcaagtac 69

<210> 13  
<211> 65  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 991

<400> 13  
ggatatccac catggacttc gggttgagct tggttttcct tgccttact ttaaaagggtg 60  
  
tccag 65

<210> 14  
<211> 39  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Primer 452

<400> 14  
tgggtcgacw gatggggstg ttgtgctagc tgaggagac 39

<210> 15  
<211> 18  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Protegrin PG-1

<400> 15

Arg Gly Gly Arg Leu Cys Tyr Cys Arg Arg Arg Phe Cys Val Cys Val

1 5 10 15

Gly Arg

<210> 16  
<211> 57  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Protegrin PG-1

<400> 16  
aggggagggtc gcctgtgcta ttgtaggcgt aggttctgcg tctgtgtcgg acgagga 57

<210> 17  
<211> 18  
<212> PRT  
<213> Artificial sequence

<220>  
<223> Novispirin G10

<400> 17

Lys Asn Leu Arg Arg Ile Ile Arg Lys Gly Ile His Ile Ile Lys Lys  
1 5 10 15

Tyr Gly

<210> 18  
<211> 36  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Forward primer 1

<400> 18  
ggtgggttgct cttccaacag gggaggtcgc ctgtgc 36

<210> 19  
<211> 23  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Reverse primer 2

<400> 19  
ccggatcctc gtccgacaca gac

23

<210> 20  
<211> 23  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Forward primer 3

<400> 20  
ggggatccgg tggcgggtggc tcg

23

<210> 21  
<211> 26  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Reverse primer 4

<400> 21  
aacatcgata gatccgccgc caccgc

26

<210> 22  
<211> 23  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Forward primer 5

<400> 22  
ggatcgatgt tgtgatgacc cag

23

<210> 23  
<211> 31  
<212> DNA  
<213> Artificial sequence

<220>  
<223> Reverse primer 6

<400> 23  
gcgggtcgac cgacttacgt ttcagctcca g

31

<210> 24  
<211> 29  
<212> DNA  
<213> Artificial sequence

<220>

<223> Forward primer 7

<400> 24

gcggtcgac gtgaagctgg tggagtctg

29

<210> 25

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> Reverse primer 8

<400> 25

gggtgttgag ctagctgaag agacggtgac

30

<210> 26

<211> 24

<212> PRT

<213> Artificial sequence

<220>

<223> Linker 2

<400> 26

Leu Asp Pro Lys Ser Cys Glu Arg Ser His Ser Cys Pro Pro Cys Gly

1

5

10

15

Gly Gly Ser Gly Gly Gly Thr Ser

20

<210> 27

<211> 72

<212> DNA

<213> Artificial sequence

<220>

<223> Linker 2

<400> 27

ctcgaccac agagctgcga gcggagccac agctgcccac cgtgcggggg tgggtccggc

60

ggtggcacta gt

72

<210> 28

<211> 28

<212> DNA

<213> Artificial sequence

<220>



<223> Forward primer 9

<400> 28

gtgggctagc ctcgacccaa agagctgc

28

<210> 29

<211> 38

<212> DNA

<213> Artificial sequence

<220>

<223> Reverse primer 10

<400> 29

aggttctcgg ggctgcccac tagtgccacc gccggacc

38

<210> 30

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> Forward primer 11

<400> 30

gggcagcccc gagaacaac

19

<210> 31

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Reverse primer 12

<400> 31

ggtggtctgc agtttaccgc gggacaggga gag

33